WO1999062576A1 - Gas driven drug delivery device - Google Patents
Gas driven drug delivery deviceInfo
- Publication number
- WO1999062576A1 WO1999062576A1 PCT/IE1998/000042 IE9800042W WO9962576A1 WO 1999062576 A1 WO1999062576 A1 WO 1999062576A1 IE 9800042 W IE9800042 W IE 9800042W WO 9962576 A1 WO9962576 A1 WO 9962576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adapter
- needle
- housing
- cover
- reservoir
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/14586—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of a flexible diaphragm
- A61M5/14593—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of a flexible diaphragm the diaphragm being actuated by fluid pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16877—Adjusting flow; Devices for setting a flow rate
- A61M5/16881—Regulating valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14204—Pressure infusion, e.g. using pumps with gas-producing electrochemical cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
- A61M2005/14252—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
- A61M2005/1426—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with means for preventing access to the needle after use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14264—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with means for compensating influence from the environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
- A61M2005/1581—Right-angle needle-type devices
Definitions
- This invention relates to a subcutaneous drug delivery device having an improved filling system.
- subcutaneous drug delivery devices A wide range of subcutaneous drug delivery devices are known in which a drug is stored in an expandable-contractible reservoir, the drug being delivered from the reservoir by forcing the reservoir to contract.
- subcutaneous includes subcutaneous, intradermal and intravenous.
- Such devices can be filled in the factory or can be filled by the pharmacist, physician or patient immediately prior to use.
- it is difficult to ensure that the drug has completely filed the reservoir i.e. that the reservoir and fluid path do not contain any air bubbles.
- this requires priming the device by filling it in a certain orientation which ensures that the air bubbles are pushed ahead of the drug, such as with the filling inlet at the bottom and the delivery outlet at the top (to allow the bubbles of air to rise during filling).
- the present invention aims to provide a subcutaneous drug delivery device having an improved filling mechanism which facilitates filling the device in an orientation-independent manner.
- a further problem associated with subcutaneous drug delivery devices is that in many cases gas generation is used to compress the reservoir. While it may be possible to ensure a constant or a controllably varying rate of gas generation (for example by passing a constant current through an electrolytic cell), this does not ensure a constant rate of drug delivery.
- the amount of compression of the reservoir depends on the amount by which the volume of the gas generation chamber expands.
- a further object of the invention is to provide a device having improved adhesion to the skin, i.e. for which there is less likelihood that the device will become detached during use.
- WO 95/13838 discloses an intradermal device of this type having a displaceable cover which is moved between a first position in which the needle is retracted before use and a second position in which the needle is exposed during use. Removal of the device from the skin causes the cover to return to the first position in which the needle is again retracted before disposal.
- the present invention aims to decrease the possibilities that the needle could become exposed by accident before or after use for example by a child playing with the device if not properly disposed of. Clearly given the risks associated with infectious diseases, particularly those carried by blood, any possibility of accidental infection must be minimised to the utmost and preferably eliminated entirely.
- the conventional method is to use a syringe, which carries the risk of accidental injury.
- the present invention has as a further aim the improvement of safety when syringes are used.
- the present invention further aims to provide a filling mechanism which facilitates loading a precise dose into the reservoir. Disclosure of Invention
- the invention provides drug delivery device comprising:
- a housing having an internal reservoir and an expandable chamber disposed relative to the reservoir, a drug delivery needle extending from the housing for penetration of the skin of a subject, the needle having an outlet for drug delivery, a fluid path defined between the delivery needle outlet and the reservoir, means for providing a gas at a controllable rate into said expandable chamber, and a flow regulating chamber, in communication with the fluid path, which is capable of volumetric changes in response to temperature and/or pressure changes.
- the expandable chamber causes contraction of the reservoir in use.
- the flow regulating chamber alters the drug delivery rate by varying the flow resistance between the reservoir and the outlet.
- the flow regulating chamber is associated with a blocking member which upon expansion of the flow regulating chamber moves within the fluid path so as to restrict the flow of drug.
- the blocking member comprises a formation provided on a displaceable member which at least partially bounds the flow regulating chamber, the formation being disposed adjacent to an inlet of a conduit forming part of said fluid path, such that restriction of the fluid path occurs when the blocking member is moved into the inlet of the conduit.
- the shape of the blocking member is adapted to cut off the fluid path completely with a predetermined degree of expansion of the flow regulating chamber.
- the formation can be shaped such that the fluid path is never entirely cut off.
- a displaceable cover is connected to the housing such that displacement of the housing relative to said cover when said cover has been applied to the skin of a subject causes the delivery needle to penetrate the skin of the subject.
- Such a displaceable cover is suitable for concealing the needle before and after application to the skin of a subject, which prevents injury and reduces the possibility of contamination of the needle.
- the expandable chamber is provided with a release valve operatively connected to the displaceable cover such that the movement of the housing relative to the cover controls the closing of the valve and thereby the sealing of the expandable chamber. This feature is not dependent on the existence of the flow regulating chamber.
- the valve enables the device to be supplied with the displaceable member positioned such that the volume of the (empty) reservoir is minimised and that of the expandable chamber maximised.
- the reservoir can be of substantially zero volume initially, with no entrapped air volume.
- the device can then be primed or loaded by filling the reservoir, for example using a syringe- or cartridge-based filling mechanism.
- the displaceable member moves to expand the reservoir and thereby contract the expandable chamber.
- the valve allows the air or other gas in the expandable chamber to be exhausted into the atmosphere.
- the device can then be applied to the skin of the user.
- the housing moves relative to the cover which is applied to the skin, not only does the needle penetrate the skin, but also (because the valve is operatively connected to the cover) the valve is closed to seal the expandable chamber. If the valve remained open then gas supplied into the expandable chamber would be free to escape and delivery would not be effected. While it would be possible for the user to close the valve manually, this would clearly leave open the possibility of error. Instead, by connecting the valve operatively to the cover, it is possible to ensure that the valve is always closed when the device is applied to the skin.
- the valve comprises two components one of which is connected to the cover and the other of which is connected to the expandable chamber, such that relative movement of the housing towards the cover causes the valve to close.
- a further aspect of the invention is that the displaceable cover is displaceable relative to the housing between a first position in which the needle is concealed from the exterior of the device and a second position in which the delivery needle protrudes from the device for penetration of the skin, the device further comprising means for locking the device in the first position after a single reciprocation of the device from the first position to the second position and back to the first position.
- the locking means is engaged automatically when the cover and housing are reciprocated relative to one another once, i.e. the housing and cover are moved relative to one another to cause the needle to protrude when the device is applied to the skin, and this relative movement is reversed when the device is removed, thereby concealing the needle but importantly, also engaging the locking means to prevent the needle from being exposed again by accident.
- the locking means comprises a mechanical latch which is brought into operation by said reciprocation.
- the latch comprises a pair of elements mounted on the cover and the housing respectively, said elements being shaped such that they can have two relative configurations when the cover is in said first position relative to the housing, namely a movable configuration in which the elements are mutually movable, and a locked configuration in which the elements are prevented from mutual movement, and wherein reciprocation of the cover and the housing causes the elements to pass from the first movable configuration, through an intermediate configuration when the cover is in said second position relative to the housing, and then to said locked configuration, thereby preventing any further movement of the cover relative to the housing.
- one of said elements is provided with a recess which is adapted to receive a projection on the other of said elements, the recess and the projection being spaced apart from one another in the movable configuration, and being in engagement with one another in the locked configuration.
- This feature helps to prevent accidental injury occurring because the needle is only exposed when the housing is moved relative to the cover, i.e. only after the user has specifically removed the removable locking member.
- the presence of said removable locking member also prevents the means for providing a gas from being actuated.
- said removable locking member comprises a laminar member inserted between said cover and said housing.
- the surface of the housing from which the needle extends or the surface of the displaceable cover, if present is of concave cross-section, such that when the device has been applied to the skin of a subject removal of the device is resisted because the cover conforms more closely to the skin.
- the needle extends from the lower surface of the housing is replaced by a tube extending from the housing, said tube being adapted to carry a drug deliver ⁇ 7 needle thereon.
- Such a device is preferred for intravenous delivery of a drug as the needle carried on the end of the tube can be accurately located in a suitable vein.
- the needle may be integral with the tube or supplied separately.
- the reservoir is separated from the expandable chamber by a diaphragm which exhibits bistable behaviour, such that in one stable state the reservoir is full and in the other stable state the reservoir is empty, the diaphragm being shaped to minimise the energy required in the transition between said stable states.
- the diaphragm is in the form of a body having a peripheral lip connected to a substantially flat central section by a flexible annular section, said flexible annular section assuming a substantially frusto-conical cross-section in one of said states and assuming an arcuate curved cross-section in the other of said states.
- the means for providing a gas comprises an electrical circuit in which any transistors are bipolar transistors having a gain of not less than 500, such that said circuit can be irradiated by ionising radiation without destroying the circuit.
- This type of transistor has been found to be advantageous as it enables the device to be sterilised using gamma radiation with the electronic components intact. While a certain loss of performance results from the irradiation, the high gain transistor still has an adequate gain after irradiation to operate reliably.
- the current gain of the or each transistor is not less than 750.
- a transistor having a rated current gain of 800 has been found to give an excellent performance after irradiation, despite the fact that irradiation lowers the current gain characteristics of the transistor by a factor of ten or more.
- the initial high gain compensates for the subsequent reduction arising from irradiation.
- the fact that the effects of irradiation can be predicted means that the performance after irradiation is reliable.
- the circuit further comprises a reference component across which a fixed potential drop is measurable, said reference component being essentially unchanged by said ionising radiation.
- a reference voltage which is not affected by the irradiation process
- the operation of the other components in the circuit may be determined by this reference voltage.
- each such transistor can be used to make an identically functioning amplifier if the output current of the amplifier is matched against a given reference component.
- said reference component comprises a light- emitting diode.
- LEDs Light emitting diodes
- said light emitting diode employs gallium arsenide as a semiconductor.
- Gallium arsenide (GaAs) LEDs are virtually unaffected by gamma rays and thus make ideal reference components according to the invention.
- the invention provides a subcutaneous drug delivery kit comprising:
- a device according to any preceding claim which is provided with a filling mechanism associated with the reservoir, the filling mechanism comprising means for receiving a filling adapter as defined in b), and
- a filling adapter comprising a body which is adapted to accommodate a cartridge, the body having means for engaging the adapter-receiving means of the device at one end thereof, means for receiving a cartridge at the other end thereof and transfer means for transferring a liquid from a cartridge to the filling mechanism of the device as the cartridge is emptied;
- the means for receiving the adapter provided on the device and the corresponding engaging means provided on the adapter together constitute a releasable locking mechanism which holds the adapter in place on the device once engaged, said locking mechanism being disengaged by the cartridge when the cartridge is emptied within the adapter.
- the kit according to the invention is advantageous because it eliminates the need for a bulky filling mechanism which accommodates the cartridge within the device, and instead employs an adapter which is releasable from the device so as to enable the filled device to be less bulky than prior art cartridge-based devices. Furthermore, the locking mechanism employed is only disengaged when the cartridge has been pushed fully home. If the cartridge used is of a type which will empty when pushed fully home, this feature ensures accurate loading of the reservoir, i.e. it is not possible to easily remove the device before the reservoir is filled with the correct dose of medicament.
- said transfer means comprises a hollow double-ended needle, one end of which is associated with the engaging means such that it communicates with the filling mechanism when the adapter is engaged with the device, and the other end of which is associated with the cartridge receiving means such that it communicates with the interior of a cartridge having a penetrable stopper when such a cartridge is received by the adapter.
- Such a hollow double ended needle can be replaced by a pair of needles which are connected by a conduit, such as a moulded conduit running through the body of the adapter and having a needle mounted at either end such that it is functionally equivalent to a double ended needle.
- a conduit such as a moulded conduit running through the body of the adapter and having a needle mounted at either end such that it is functionally equivalent to a double ended needle.
- both ends of the needle are disposed within the body of the adapter such that they are recessed from the exterior of the body when the adapter is disengaged from the device.
- this arrangement is preferable, as it allows the adapter to be disposed of without fear of accidental injury occurring from casual handling of the adapter.
- the releasable locking mechanism comprises a pair of locking members provided on the adapter receiving means and the corresponding engaging means, respectively, one of said locking members being movable between a locking position and a disengaging position, and said movable locking member being disposed relative to the body such that, in use, when a cartridge is emptied within the body, said movable locking member is moved from the locking position to the disengaging position under the action of the cartridge.
- the body can receive the cartridge within a passage having a diameter sufficient to completely accommodate the cartridge, but with the end of the passage (only reached by the cartridge when the cartridge is pushed fully home) being of slightly narrower diameter on account of a projection provided on the movable locking member.
- the cartridge when the cartridge is pushed fully home, it contacts the movable locking member and pushes it out of the way, thereby disengaging the locking mechanism.
- said movable locking member is resiliently biased towards the locking position.
- said movable locking member is a latch which automatically locks the adapter and device to one another when engaged together.
- the cartridge is emptied by moving the penetrable stopper against the adapter.
- the invention provides a subcutaneous drug delivery kit comprising:
- a device according to any preceding claim further comprising a filling mechanism associated with the reservoir, the filling mechanism comprising means for receiving a filling adapter as defined in b), and
- a filling adapter comprising a body which is adapted to receive a syringe, the body having means for engagement with the adapter-receiving means of the device at one end thereof, syringe-receiving means at the other end thereof and transfer means for transferring a liquid from the syringe to the filling mechanism of the device as the syringe is emptied, said transfer means comprising a conduit associated with the syringe receiving means, the conduit leading to a needle which is associated with the engagement means and is disposed within the body of the filling adapter.
- the adapter preferably receives the syringe without a needle being provided on the syringe. This fact, along with the fact that the needle on the adapter is recessed from the exterior of the adapter body means that a conventional syringe (minus needle) can be used to fill the device without any risk of accidental injury occurring.
- the needle is disposed within the body of the filling adapter such that it is recessed from the exterior of the body when the adapter is disengaged from the device. This helps to avoid accidental injury or infection occurring.
- the invention provides a method of filling a drug delivery device, comprising the steps of:
- the invention provides a drug delivery device having a drug reservoir, the reservoir being associated with a filling mechanism comprising filling adapter receiving means; providing a filling adapter having a first end for engagement with the adapter receiving means, and a second end for receiving a syringe; causing the filling adapter receiving means to receive the filling adapter; causing the second end of the filling adapter to receive a syringe having liquid stored therein and a needle; providing a conduit for communication between the liquid stored within the syringe and the first end of the filling adapter: and emptying the syringe and concurrently transferring the liquid from the syringe to the device via the conduit.
- the invention provides a filling adapter as defined above and a diaphragm as defined above.
- Fig. 1 is a sectional side view of a first embodiment of drug delivery device according to the invention
- Fig. 2 is an exploded perspective view of the flow regulating chamber and needle assembly of the first embodiment of the device of Fig. 1;
- Fig. 3 is an enlarged sectional side view of the flow regulating chamber and needle assembly of the first embodiment of the device of Fig. 1 ;
- Figs. 4-6 are sectional side views of a second embodiment of drug delivery device according to the invention, shown before, during and after use, respectively;
- Figs. 7-9 are enlarged perspective views of the locking mechanism of the device of Figs. 4-6, shown before, during and after use, respectively;
- Fig. 10A, 10B and IOC are schematic elevations of a first alternative embodiment of a locking mechanism, shown before use, during use and after use, respectively;
- Fig. 10D is a perspective view of the locking mechanism as shown in Fig. 10A;
- Fig. 11A, 11B and 11C are schematic elevations of a second alternative embodiment of a locking mechanism, shown before use, during use and after use, respectively;
- Fig. 1 ID is a perspective view of the locking mechanism as shown in Fig. 11A;
- Fig. 12A, 12B and 12C are schematic elevations of a third alternative embodiment of a locking mechanism, shown before use, during use and after use, respectively;
- Fig. 12D is a perspective view of the locking mechanism as shown in Fig. 12A;
- Figs. 13A, 13B and 13C are schematic elevations of a fourth alternative embodiment of a locking mechanism, shown before use, during use and after use, respectively;
- Fig. 13D is a side elevation of the locking mechanism as shown in Fig. 13 A;
- Fig. 13E is a perspective view of the locking mechanism as shown in Fig. 13A;
- Figs. 14 and 15 are sectional elevations of a third embodiment of drug delivery device according to the invention, shown before and during use, respectively;
- Fig. 16 is a partially cut away perspective view of the lower part of the housing on the third embodiment of the device of Figs. 14 and 15, including various components housed therein;
- Fig. 17 is an exploded perspective view of the electrolytic cell used in the embodiment of Figs. 14 and 15;
- Fig. 18 is a sectional side view of the electrolytic cell used in the embodiment of Figs. 14 and 15;
- Figs. 19 and 20 are sectional side views of a fourth embodiment of drug delivery device according to the invention, shown before and during use, respectively;
- Fig. 21 is a sectional plan view of a drug delivery kit comprising the first embodiment of Fig. 1, a filling adapter and a medicament cartridge;
- Fig. 22 is a perspective view of a subassembly used in the adapter shown in Fig. 21;
- Figs. 23 and 24 are sectional side views of the drug delivery kit of Fig. 21, shown during and after filling of the device, respectively;
- Figs. 25 and 26 are sectional side views of fifth and sixth embodiments, respectively, of drug delivery device according to the invention.
- Figs. 27 and 28 are sectional side views of a diaphragm suitable for use in a device according to the invention.
- Fig. 29 is a diagram of an electronic controller circuit suitable for use in a device according to the invention.
- Figs. 30 and 31 are perspective views of the top side and underside, respectively, of a displaceable cover from a device according to the invention.
- a subcutaneous drug delivery device in Fig. 1 there is indicated, generally at 10, a subcutaneous drug delivery device according to the invention.
- a housing 11 defines a reservoir 12 which is partially bounded by an elastomeric diaphragm 13 which allows the reservoir 12 to expand and contract.
- Diaphragm 13 also bounds an expandable chamber 14 such that expansion of the expandable chamber 14 causes the reservoir 12 to contract and vice versa.
- reservoir 12 is at full volume and contains a drug, while expandable chamber 14 is at minimum volume.
- a circuit board 15 having an electrolytic cell mounted thereon (explained in greater detail below) is mounted in the lower part 16 of housing 11.
- the electrolytic cell feeds a gas in use into expandable chamber 14 via an aperture 17 in a supporting member 18.
- Reservoir 12 is provided with an inlet 19 which is in communication with a filling mechanism 20 (explained in greater detail below).
- a delivery needle 21 provided with an outlet 22 is in communication with reservoir 12 via a fluid path 23 which is indicated by arrows.
- the fluid path 23 passes around an air-filled flow- regulating chamber which comprises a top member 24, annular member 25 and diaphragm 26.
- the fluid path also passes via a needle holder 27 to the needle 21.
- the inlet to the needle 21 is partially restricted by a projection 28 on diaphragm 26, such that any upward movement of projection 28 reduces resistance to flow and any downward movement of projection 26 increases flow resistance.
- the flow regulating chamber can be seen in exploded view.
- top member 24, annular member 25 and diaphragm 26 can be seen.
- Annular member 25 accommodates diaphragm 26, and the three components 24,25,26 fit together to form an airtight chamber which is positioned above needle holder 27.
- the inlet in needle holder 27 leading to needle 21 can be clearly seen on the top surface of needle holder 27. It is into this inlet that projection 28 (Fig. 1) extends.
- a displaceable cover 29 attached to the housing 11 by a hinge 30.
- Displaceable cover 29 which, in use, is affixed to the skin using an adhesive coating 29' provided on the surface thereof distal from the housing ("the underside").
- the displaceable cover 29 has a concave shape when viewed from the underside. This shape is advantageous because if a flat or convex surface is provided, the edges of the cover 29 will be more easily peeled away from the skin by accident, i.e. the use of a convex surface is less likely to have protruding edges, and the force required to peel the device away is a shear force rather than a simple peeling force.
- the housing 11 is covered by a protective top cover 32 which can provide a more aesthetically pleasing appearance to the device, as well as one which is ergonomically more advantageous for the user.
- An aperture in protective top cover 32, indicated at 33, allows a transparent portion 34 of housing 11 to be seen, thereby allowing the user to visually check the reservoir to see whether drug is present.
- the protective top cover 32 also protects the housing 11 and its component parts if the device 10 is mishandled or dropped
- Fig. 3 the flow regulating chamber is shown in greater detail.
- the chamber indicated generally at 35, comprises top member 24, annular member 25, and diaphragm 26, as explained above.
- the construction ensures that an airtight space 36 exists in the interior of chamber 35.
- a fluid path between the reservoir and the needle (Fig. 1) is shown with heavy arrows.
- projection 28 on diaphragm 26 extends into the inlet 37 in needle holder 27 leading to the needle. The fluid thus has to push up on diaphragm 26 in order to reach the needle. Little force is required to do this, as the air in chamber 35 is compressible.
- a further feature of the device of Figs. 1-3 is an o-ring 38 located on displaceable cover 29 (see Fig. 1).
- O-ring 38 forms a seal with needle holder 27 and thereby assists in protecting the puncture point of the needle 21 into the skin of the user from contact with soap or water when the user takes a shower. If water contacts the needle 21 , needle 21 may assist in water being drawn into the puncture by a wicking mechanism.
- adhesive 29' on displaceable cover 29 prevents water from reaching the needle via the underside of cover 29, and o-ring 38 prevents water from reaching the needle via the upper side of displaceable cover 29.
- Figs. 4, 5 and 6 show a device similar to that of Fig. 1 before, during and after use, respectively.
- the device, indicated generally at 50, differs slightly from the Fig. 1 device and accordingly different reference numerals are used in relative to Fig. 1.
- the device 50 is shown in Fig. 4 with the needle 51 concealed by the displaceable cover 52 because displaceable cover 52 is displaced relative to housing 53 about hinge 54.
- a removable tab 55 prevents displaceable cover 52 from being moved towards housing 53, as will be described further below.
- the underside 56 of displaceable cover 52 is coated with a contact adhesive, and during storage, the adhesive is protected by a release liner (not shown).
- the adhesive-coated underside 56 is pressed against the skin to ensure good adhesion (the concave surface assists in obtaining good adhesion) and the tab 55 is removed.
- the housing 53 is then pushed towards the skin and the needle 51 penetrates the skin as the displaceable cover 52 and housing 53 move together about hinge 54, leading to the configuration shown in Fig. 5.
- a start button (not shown) is pressed to activate the gas generating electrolytic cell 57 (see Fig. 5).
- a diaphragm 58 is pushed upwards to drive a liquid drug from reservoir 59 (which was filled before use via inlet 60) and thereby force the medicament through a fluid path 61 around flow regulating chamber 62 (as explained above in relation to Figs. 1-3) and to the patient via delivery needle 51.
- the diaphragm 58 will have moved up such that the space occupied by the reservoir 59 at the beginning of delivery (see Figs. 4 and 5) is now occupied by the expandable chamber 60 (see Fig. 6), since the expansion of the expandable chamber causes contraction of the reservoir.
- the device 50 is removed from the skin by pulling upwards on upper protective cover 63 (Fig. 6) causing the needle 51 to be retracted behind displaceable cover 52 once again because the adhesive force holding the displaceable cover 52 against the skin is greater than the force exerted by the locking mechanism 64 (explained in greater detail below).
- the locking mechanism 64 holds the displaceable cover 52 permanently in the position shown in Fig. 6, i.e. away from the housing 53 with the needle 51 concealed.
- Fig. 7 shows locking mechanism 64 in greater detail, with the protective top cover 63 removed for illustrative purposes.
- the locking mechanism 64 is illustrated before use, i.e. when the displaceable cover is positioned as shown in Fig. 4. In other words, there is a gap between the housing 53 and the displaceable cover 52 and the needle 51 (Fig. 4) is recessed in this gap and thereby concealed by the displaceable cover 52.
- a projection 65 mounted on the front of housing 53 is positioned at the upper end of a slot 66.
- Slot 66 has an enlarged portion 67 at the lower end and is provided with wedge projections 68,69 at the exterior surface of the upper portion thereof.
- Slot 66 is formed in a member 70 which is attached to displaceable cover 52 by connecting arms 72 which allow a slight degree of flexibility.
- a widened rib (not shown in Fig. 7) is provided on the projection 65, and the width of this rib is greater than that of the upper portion of the slot 66.
- the member 70 is biased slightly against this rib.
- the removable tab (see Fig. 4) is positioned so as to engage wings 71 and prevent them from moving towards the cover 52. This effectively prevents the entire housing from being moved towards the cover and prevents the device from being activated.
- the tab is removed, as shown in Fig. 7, the displaceable cover 52 can be snapped towards the housing 53 by pressing down on the housing. This results in the locking mechanism adopting the configuration shown in Fig.
- FIG. 4 An additional feature of the device of Figs. 4-8 relative to that of Fig. 1 can be seen with reference to Figs. 4-6.
- a pair of projections 74 grip the flow regulating chamber 62 before use to block the path between reservoir 59 and needle 51 before use (Fig. 4).
- the projections 74 are resilient and move together when flow regulating chamber 62 moves downwards. In this position the projections 74 hold flow regulating chamber 62 in a fixed position both during delivery (Fig. 5), and when the device is removed from the skin (Fig. 6).
- a further feature of the embodiment of Figs. 4-6 is an annular elastomeric inwardly extending lip 75 which seals the skin at the point of entry of the needle 51 in the same manner as the o-ring 38 in the Fig. 1 embodiment, and thereby reduces the danger of infection due to wicking by the needle of substances into the skin.
- Figs. 10A-10D, 11A-11D, 12A-12D, and 13A-13E Four alternative embodiments of different locking mechanisms according to the invention are shown in Figs. 10A-10D, 11A-11D, 12A-12D, and 13A-13E.
- the mechanism is shown schematically in "pre-use” (A), "in-use” (B) and “post-use” (C) configurations as well as in one or two perspective views (D/E).
- the mechanism can in each case be moved from position A to position B and from position B to position C with little difficulty (although generally some resistance is present to prevent spontaneous or accidental movement), but once in position C, the mechanism is effectively locked permanently and is no longer capable of operation.
- the first alternative embodiment of a locking mechanism comprises a resilient arm and related assembly and is shown in Figs 10A-10D.
- the locking mechanism is indicated generally at 80 and comprises a biasing member 81 and a resilient strut 82 mounted on the housing 83, and the resilient arm 84 and a post 85 mounted on the displaceable cover 86.
- the resilient arm 84 is flexibly hinged at the base thereof 87.
- biasing member 81 pushes the resilient arm 84 against the post 85.
- the resilient arm 84 and post 85 are mutually shaped to allow the arm 84 to pass over the top of the post 85, where it latches (see Fig. 10B) and is prevented from returning to the position shown in Fig. 10A.
- the arm 84 In passing over the top of the post 85, the arm 84 acts against the resilient strut 82, momentarily bending the strut 82 away from the biasing member 81, although when the arm 84 has passed fully over the top of the post 85 the strut 82 has returned to its relaxed (straight) position (Fig. 10B).
- FIG. 10D shows the mechanism in the position illustrated in Fig. 10A.
- An additional feature visible in Fig. 10D is a snap mechanism comprising an arm 90 depending from either side of the housing 83.
- a raised protuberance 91 on the inner surface of each arm 90 acts against a sloped surface 92 on the displaceable cover 86 to provide resistance to movement.
- the effect of the snap mechanism is to add further resistance to any unintended relative movement between the housing 83 and the displaceable cover 86.
- a further effect is that the movement of the housing relative to the cover between the configurations of Figs 10A and 10B, and the configurations of Figs 10B and 10C, is extremely rapid, causing the penetration of the needle into the skin and the removal of the needle from the skin to be quick and painless.
- the second alternative embodiment of a locking mechanism of the present invention comprises an inverted V-shaped assembly and is shown in Figs 11A-1 ID.
- the locking mechanism is indicated generally at 100 and comprises a member 101 resiliently mounted on housing 102, and a pin 103 supported in a frame 104 mounted on displaceable cover 105.
- Member 101 defining a slot 106 therein of the generally inverted V-shape such that it has an outer slot portion 107 connected at the upper end thereof to an inner slot portion 108, and a dividing member 109 between the outer and inner slot portions 107, 108 below the upper ends.
- the (fixed) pin 103 moves up outer slot 107, acting against dividing member 109 until it springs past dividing member 109 at the top of the outer slot. In the position shown in Fig. 11B, the pin 103 is located above the top of the inner slot 108.
- pin 103 When the housing 102 is subsequently pulled away from the displaceable cover 105 (moving from Fig. 1 IB to Fig. 11C, the pin moves down inner slot 108, acting against the dividing member 109 to push member 101 sideways.
- pin 103 locates a recess 110 (see Fig. 1 IB) in the lower end of inner slot 108, which allows the member 101 to relax slightly but still keeping a certain degree of stress on member 101 by holding it away from the equilibrium position relative to the housing 102. In this way, pin 103 latches into recess 110 and locks the mechanism 100 permanently in the "post-use" configuration.
- Fig. 1 ID the mechanism 100 can be seen in the "pre-use” configuration, with member 101, housing 102, pin 103, frame 104, and displaceable cover 105 visible.
- the third alternative embodiment of a locking mechanism of the present invention comprises generally a rotatable pawl assembly and is shown in Figs. 12A-12D.
- the mechanism indicated generally at 120, comprises a rotatable pawl 121 mounted on the displaceable cover 122 and which is rotated by an arm 123 in moving from the "pre-use" to "in-use” positions (Figs. 12A and 12B, respectively).
- a recess 124 (Fig. 12 A) receives a projection 125 located on a resilient portion 126 of displaceable cover 122, providing a degree of resistance to further movement.
- rotatable pawl 121 acts against a flexible strut 127 depending from housing 128.
- arm 123 When the rotatable pawl 121 is in the Fig. 12B position, further clockwise rotation of the pawl is prevented by arm 123.
- strut 127 acts against a projection 129 urging the rotatable member 121 in a clockwise direction, but arm 123 prevents such rotation.
- strut 127 springs past projection 129 to sit in a recess above projection 129, and arm 123 clears the upper corner of rotatable pawl 121.
- arm 123 prevents any counter-clockwise rotation of the rotatable pawl 121, while strut 127 prevents any clockwise rotation thereby locking the rotatable pawl 121 in position and preventing any further downward movement of housing 128 towards displaceable cover 122.
- the fourth alternative embodiment of a locking mechanism of the present invention comprises generally a flexible post assembly as shown in Figs. 13A-13E.
- the locking mechanism is indicated generally at 130 and comprises a vertical flexible post 131 (see Figs. 13D and 13E) mounted on the displaceable cover 132 and having a projection 133 extending therefrom towards a sloped surface 134 on the housing 135.
- a slot 136 in surface 134 connects two apertures, namely a lower aperture 137 (see Fig. 13B) which is of smaller diameter than the widest part of projection 133, and an upper aperture 138 which is of larger diameter than the widest part of projection 133.
- projection 133 In the "pre-use” position, projection 133 is positioned at the lower aperture. As the housing moves towards the “in-use” position (Fig. 13B) the flexible arm 131 is bent back until projection 133 reaches the upper aperture 138 whereupon it springs back into position as projection 133 moves through the upper aperture 138. In moving to the "post-use” position, projection 133 is constrained by the slot 136 and arm 131 is bent forward until projection 133 reaches lower aperture 137 which provides a recess for projection 133 to spring back into (but not through). Because arm 131 remains bent forward slightly, this effectively traps projection 133 in lower aperture 137 and thereby holds the mechanism permanently in the "post-use” configuration, as shown in Fig. 13C.
- FIG. 14 there is indicated, generally at 140, another drug delivery device according to the invention similar in many respects to the embodiments previously described.
- Device 140 has a protective upper cover 141, housing 142, displaceable cover 143, delivery needle 144, flow regulating chamber 145 and three position locking mechanism 146.
- the internal space of the embodiment of Fig. 14 defines an expandable chamber 147 when the diaphragm 148 is in the position shown or a reservoir when the diaphragm is in the position shown in dotted outline at 149.
- the expandable chamber 147 is initially air filled (Fig. 14 shows the device in the pre-use configuration before medicament has been loaded). Thus, the reservoir is substantially of zero volume. Expandable chamber 147 communicates with the atmosphere via an open valve 150.
- the reservoir is initially of substantially zero volume, it does not require filling in any particular orientation. While prior art devices have required careful loading in order to ensure that all air bubbles are vented from the drug supply before delivery begins, the only air in the drug path of the device of Fig. 14 is in the short, narrow portion of the device between the reservoir and the needle 144. Thus, when drug enters the reservoir it immediately pushes the small amount of air ahead of it through the narrow space towards the needle 144, irrespective of the orientation of the device 140. By filling with the drug until a drop of the drug appears on the end of the needle one can be sure that no air remains in the fluid path.
- the diaphragm 148 When the device 140 has been filled with drug, the diaphragm 148 is at the position shown at 149, and the valve 150 is open. However, when the displaceable cover 143 is applied to the skin, and the housing is pushed downwards, the valve 150 is closed and the closing of the valve actuates a switch 151 to begin generation of gas by an electrolytic cell 152 (described in more detail below).
- the device 140 is then in the "in-use" position shown in Fig. 15, with reservoir 147 filled with drug, the diaphragm 148 in position 149, valve 150 and switch 151 closed, and electrolytic cell 152 actuated to generate a gas and hence begin delivery of drug from reservoir 147 to the patient through delivery needle 144.
- Valve 150 is closed by a connecting member 153 which is connected to displaceable cover 143.
- connecting member 153 fits into valve 150 and pushes it home to seal the expandable chamber 147 (the area below diaphragm 149) from the atmosphere.
- a gas is generated by the electrolytic cell 152, it pressurises the expandable chamber 147.
- a coloured plastics member 154 forming part of locking mechanism 146 protrudes through an aperture 155 in protective upper cover 141 when the device is in the position as shown in Fig. 15.
- the coloured member 154 visually indicates that the device has been actuated.
- Fig. 16 is a detail view of the lower section 156 of the housing
- Lower section 156 houses a battery 157 and an electrolytic cell 158, both mounted on a printed circuit board (PCB) 159.
- PCB 159 can be provided with controlling circuitry as required in order, for example, to vary the rate of delivery, stop delivery if the rate of gas generation is too high, or control the operation of the device 140 in any other way required.
- the device is a disposable single-rate device which does not require advanced controlling circuitry, but more sophisticated devices are of course within the scope of the invention.
- a cylindrical outlet 160 is formed in section 156, and this provides a valve seating for valve 150.
- valve 150 When valve 150 is pushed upwards into outlet 160 it makes an airtight seal, as shown in Fig. 15.
- Recess 161 in valve 150 tightly accommodates connecting member 153 (Fig. 15), and the force used to push housing 142 down onto displaceable cover 143 as described above is sufficient to jam connecting member 153 in valve 150.
- This design enables the device to be removed from the skin by pulling housing 142 away from displaceable cover 143 to the "post-use” position, causing connecting member 153 (which is permanently mounted on displaceable cover 143 and at this stage jammed into valve 150 also) to pull the valve 150 down and out of outlet 160 so as to open the valve.
- connecting member 153 which is permanently mounted on displaceable cover 143 and at this stage jammed into valve 150 also
- valve 150 when valve 150 is closed it actuates a switch 151 (see Fig. 15) which comprises a fixed contact 162 and a rocking contact 163. This completes a circuit to connect battery 157 to electrolytic cell 158.
- switch 151 When valve 150 is pulled downwards as the device is removed from the skin, the switch should automatically disconnect because of the resilience of rocking contact 163 which pivots about a fulcrum 164.
- the opening of the valve 150 is generally a redundant feature and is important as a safety feature if the switch does not automatically disconnect (leading to an unwanted continuation of delivery or, if the reservoir is already empty, to a build up of gas pressure inside the device).
- the electrolytic cell 158 comprises (see also Figs. 17 and 18) a body 165 defining an internal space 166 for an electrolyte and through which a pair of electrodes 167 pass, each electrode being connected to a terminal of battery 157 (Fig. 16).
- the internal space 166 is enclosed above and below by a pair of hydrophobic filters 168,169. These filters 168,169 retain the electrolyte but allow gas generated in the cell 158 to be released to the expandable chamber 147.
- the body 165 is provided with a seating 170 above and below, into which the filters 168,169 fit and are sealed in place.
- the cell 158 is then sealed above and below by aluminium foil layers 171,172.
- a connecting cell 174 sealed at both ends by foil layers 171,172 enables gas passing through the hydrophobic filters 168,169 to be released, once the top foil layer 171 has been pierced.
- a gap adjacent to the seating 170,171 enables gas escaping through hydrophobic filters 168,169 to reach the connecting cell 174.
- the foil layer 171 is pierced by a spike 175 carried on rocking contact 164 (see Fig. 16).
- a hydrophobic filter 176 (see Fig. 17) is also carried in the body 165 to enable the cell 158 to be filled with electrolyte by injection.
- a further embodiment 180 of the invention is shown.
- This embodiment differs from the embodiment of Figs. 14-18 only in that the valve member 181 is not held by the displaceable cover 182 when the device 180 is removed from the skin after use.
- the valve 181 nevertheless achieves the primary purpose of allowing the internal space 183 to be occupied entirely by the expandable chamber when received by the user, with the diaphragm 184 moving to the position shown at 185 when the device 180 is loaded with medicament, which means that no air bubbles can be entrapped in the reservoir during filling, and the reservoir can thus be filled quickly and easily.
- the valve 181 closes automatically when the housing 186 is pressed towards the displaceable cover 182 (see Fig. 20).
- FIG. 21 shows a device 190 according to the invention which is identical to the device of Fig. 1, together with a filling adapter 191 and a drug-containing cartridge 192.
- Cartridge 192 is cylindrical in shape, closed at one end 193 thereof and sealed at the other end 194 by an elastomeric stopper 195 which is fittably mounted in the cartridge 192. Because the cartridge's liquid-filled internal space 196 is sealed, the stopper 195 is prevented by the incompressible nature of the liquid from moving in either direction.
- the adapter 191 comprises a housing 197 in which a cannula subassembly 198 is mounted.
- the subassembly 198 (see Fig. 22) comprises a plastic body 199 moulded in two halves 200,201, which when assembled together clamp a double-ended hollow needle or cannula 202 in place.
- Device 190 is provided with a socket 203 for receiving adapter 191.
- a cylindrical projection 204 on the end of adapter 191 is designed to fit into socket 203, and also to conceal cannula 202 to prevent injury before and after adapter 191 is mounted on device 190.
- a self-sealing penetrable plug 205 mounted in socket 203 leads to a conduit 206 and an inlet for the reservoir (see inlet 19 in Fig. 1).
- Subassembly 198 is mounted in a channel 207 of adapter 191 such that it can be pushed inward until a shoulder 208 meets the end of the structure 209 defining channel 207. At this point the cannula 202 will penetrate self-sealing member 205 enabling communication between cannula 202 and the reservoir of device 190.
- cartridge 192 is pushed into adapter 191, whereby stopper 195 causes subassembly 198 to be pushed inwards and cannula 202 to penetrate self-sealing member 205. Since the subassembly can move no further inward, further pushing of the cartridge into the adapter causes cannula 202 to penetrate stopper 195, thus putting drug- filled space 196 in indirect communication with the reservoir of device 190.
- stopper 195 Since the stopper 195 is then held by subassembly 198, further pushing of the cartridge 192 inwards causes the stopper 195 (which remains stationary) to move relative to the cartridge 192 (which is progressively accommodated in the interior of adapter 191), with a consequent emptying of the contents of the cartridge 192 through the cannula 202 into the reservoir of device 190.
- Fig. 23 shows a sectional elevation of the components shown in sectional plan view in Fig. 21 , after the cartridge 192 has been pushed most of the way home into adapter 191. It can be seen that at this point, stopper 195 (penetrated by cannula 202 which also penetrates self-sealing member 205) has almost reached the end 203 of cartridge 192.
- Adapter 191 is not only held by the fit of projection 204 into socket 203, but also by a releasable locking mechanism 210 comprising an aperture 211 on device 190 and a resilient catch 212 on adapter 191 which is biased into the position shown in Fig. 23 so as to hold adapter firmly in place on device 190.
- the adapter and the device are sold together in kit form, optionally with the adapter already mounted on the device.
- cartridge 192 When cartridge 192 is pushed fully home it acts on a sloped section 213 of wall 214 of adapter 191 so as to push resilient catch 212, which is an extension of wall 214 downwards and thereby disengage locking mechanism 210, allowing adapter 191 to be removed from device 190.
- Fig. 24 shows the kit after cartridge 192 has disengaged catch
- catch 212 is only disengaged when cartridge 192 is fully emptied (i.e. pushed fully home), one can ensure that the reservoir is loaded with exactly the correct amount of drug every time, thereby eliminating human error and making the kit more suitable for home administration.
- the adapter 191 can be safely disposed of without risk of injury.
- the adapter 191 allows the drug to be transferred to the reservoir with sterility ensured, since the user does not at any time have to handle any of the components in the fluid path.
- Fig. 25 shows a device according to the invention, indicated generally at 220, which differs from previous embodiments primarily in that instead of a needle extending directly from the housing 221, a tube 222 extends from the housing 221 and carries a connector 223 thereon to which a needle may be affixed before use.
- This device is particularly suitable for intravenous drug delivery because the tube 222 allows the needle to be accurately positioned in a vein.
- Fig. 26 shows an alternative intravenous embodiment, indicated generally at 230.
- the displaceable lower cover has been omitted and the device is actuated by a contact switch 231 positioned on the underside of the housing 232.
- switch 231 When the device is applied to the skin, switch 231 is pressed inwards (to the position shown in Fig. 26), thereby closing an electrical circuit and actuating a gas generating electrolytic cell 233 in the manner previously described.
- the cover can be omitted without interfering with other functions of the device.
- Fig. 27 shows the elastomeric diaphragm, indicated generally at 240, utilised in the above-described devices according to the invention.
- Diaphragm 240 can also be used in other drug delivery devices according to the invention.
- Diaphragm 240 is shown in Fig. 27 in its relaxed position, as it would be when the reservoir is empty (see Fig. 6, for example).
- the diaphragm 240 substantially has the form of a truncated cone having a sloped portion 241 surrounding a flat portion 242, with a lip 243 surrounding sloped portion 241 (lip 243 is used to attach diaphragm 240 to the housing of a drug delivery device).
- Fig. 28 shows diaphragm 240 in the configuration in which the reservoir is full (see Fig. 1, for example).
- the central portion 242 is still flat, and the surrounding portion 241 has an arcuate curved cross-section, in the form of a substantially inverted U shape.
- the diaphragm 240 is bistable, such that it is stable in either the Fig. 27 or the Fig. 28 configuration.
- a particular advantage has been found to result from the fact that in moving from the reservoir full (Fig. 28) configuration to the reservoir empty (Fig. 27) configuration, very little energy is needed.
- bistable arrangements Unlike many bistable arrangements, only minimal force is required to move between the stable configurations. In many bistable arrangements a substantial amount of energy is required to move from one configuration to a midpoint, at which the amount of stored energy is relatively high, following which the stored energy is released to complete the transition.
- the diaphragm 240 rather than flipping between configurations, makes a smooth transition. However, in contrast to a completely pliable body, which cannot be depended on to exert force uniformly, the diaphragm 240 will behave dependably since it is constrained in its movement between configurations.
- Fig. 29 shows a circuit diagram of a controlling circuit particularly useful or a drug delivery device according to the invention.
- the components shown are battery B l, switch SI (activated by applying the device to the body), fixed resistors R1-R6 and R9-R10, variable resistors R7 and R8, capacitor Cl, transistors Q2-Q6, measurement terminals TP1 and TP2, light emitting diode LED, and load Ul which represents the electrolytic cell or other gas generating means.
- Reference numeral 251 denotes a section of the circuit 250 which functions as a current driver
- reference numeral 252 denotes a section of the circuit 250 which functions as an error circuit.
- the current through the electrolytic cell Ul determines the potential drop across variable the resistance comprising resistors R7 and R8 (which may be adjusted to calibrate the device or set the delivery rate). This potential drop is compared by the error circuit with the potential drop across a reference resistor RI, which itself depends on the voltage drop across the LED.
- resistor RI is chosen to provide a potential drop equal to the drop measured across R7 and R8 when the correct current is flowing through cell Ul.
- the error circuit 252 forces the driver 251 to increase the current flow to the correct value. In practice, the error circuit continually ensures that the current does not deviate from the correct value by constant feedback operation.
- Each of the transistors in the circuit 250 is a silicon-based bipolar transistor.
- the advantage of using bipolar transistors in particular is that they have been surprisingly discovered to withstand gamma radiation to a far greater extent than other types of transistors.
- the use of silicon as semiconductor is not essential but this material is currently less expensive than many other semiconductors. It has been found that by employing a circuit in which the or each transistor is a bipolar transistor, the circuit and hence the entire device can be subjected to intense gamma irradiation as a means of sterilising the device after manufacture. Conventional integrated circuits are destroyed by the intense radiation required to sterilise a device quickly.
- a dose of 2.5 Mrad (25 kJ/kg) of gamma radiation may be required to sterilise a device.
- 2.5 Mrad (25 kJ/kg) of gamma radiation may be required to sterilise a device.
- the electronic components used in space missions such as the U.S. Space Shuttle missions. It was found that the same degree of radiation resistance was not required because the absorbed dose measured on the Space Shuttle averages approximately 0.4-0.5 Mrad.
- the drop in current gain exhibited after irradiation can be compensated for in advance.
- This drop in gain can be of the order of a tenfold drop or more, but can be predicted well in advance.
- current values which are sufficiently low the drop in voltage at the silicon junction of the transistor occurring as a result of the irradiation only slightly affects performance.
- the LED used is a gallium arsenide (GaAs) based LED which has been found to provide particularly good resistance to gamma radiation.
- GaAs gallium arsenide
- the components and circuit employed have been found to be suitable for gamma irradiation, following which they give a well predictable performance in use. This enables the manufacture to be completed more efficiently, with the assembled device sterilisable by gamma radiation.
- Fig. 30 is a perspective view of the top side of a displaceable cover 160 forming part of a device according to the invention.
- Fig. 31 is a perspective view of the underside of cover 160. Such a cover is described generally above in relation to the embodiment of Figs. 4-8, for example.
- the cover 160 is provided with formations 161 forming part of a locking mechanism as described above, with an aperture 162 through which a delivery needle protrudes in use, and with hinge formations 163 which enable the cover 160 to be displaced relative to the housing between first and second positions as previously described.
- the cover 160 is shaped to improve retention of the device against the skin: thus the top side 164 (Fig. 30) is convex, and the underside 165 (Fig. 31) from which the needle protrudes in use is concave. Accordingly, when the device has been applied to the skin of a subject removal of the device is resisted because the cover 160 conforms more closely to the skin. It is less likely that the device will peel from the skin without a conscious effort by the user since there is a lower likelihood of the periphery of the cover being detached from the skin.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002334174A CA2334174A1 (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
JP2000551829A JP2002516723A (en) | 1998-06-04 | 1998-06-04 | Gas-powered drug delivery device |
AU77859/98A AU7785998A (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
EP98925906A EP1082151A1 (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
PCT/IE1998/000042 WO1999062576A1 (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IE1998/000042 WO1999062576A1 (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999062576A1 true WO1999062576A1 (en) | 1999-12-09 |
Family
ID=11042512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IE1998/000042 WO1999062576A1 (en) | 1998-06-04 | 1998-06-04 | Gas driven drug delivery device |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1082151A1 (en) |
JP (1) | JP2002516723A (en) |
AU (1) | AU7785998A (en) |
CA (1) | CA2334174A1 (en) |
WO (1) | WO1999062576A1 (en) |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002165A2 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharma International Limited | Needle device and method of operation thereof |
WO2001089607A3 (en) * | 2000-05-23 | 2002-02-28 | Elan Pharma Int Ltd | Gas driven drug delivery device |
WO2003028784A2 (en) | 2001-10-04 | 2003-04-10 | Smiths Medical Md, Inc. | Right angle safety needle |
EP1502613A1 (en) * | 2003-08-01 | 2005-02-02 | Novo Nordisk A/S | Needle device with retraction means |
US6981977B2 (en) | 2001-10-26 | 2006-01-03 | Atrium Medical Corporation | Body fluid cartridge exchange platform device |
US7066922B2 (en) | 2001-10-26 | 2006-06-27 | Massachusetts Institute Of Technology | Transdermal transport device with suction |
WO2007079115A3 (en) * | 2005-12-28 | 2007-11-29 | Smiths Medical Md Inc | Removable sharps device for accessing a portal reservoir |
WO2009137780A2 (en) * | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable pumps and cannulas therefor |
US7887508B2 (en) | 2006-03-14 | 2011-02-15 | The University Of Southern California | MEMS device and method for delivery of therapeutic agents |
EP2308365A2 (en) | 2000-06-27 | 2011-04-13 | Intuity Medical, Inc. | Analyte monitor |
AU2006332793B2 (en) * | 2005-12-28 | 2011-05-26 | Smiths Medical Asd, Inc. | Removable sharps device for accessing a portal reservoir |
US8021357B2 (en) | 2005-05-27 | 2011-09-20 | Olympus Corporation | Body-insertable apparatus |
US8158143B2 (en) | 2000-07-14 | 2012-04-17 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
US8231609B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US8348897B2 (en) | 2008-05-08 | 2013-01-08 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
US8690796B2 (en) | 2002-04-19 | 2014-04-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8845550B2 (en) | 2001-06-12 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8845549B2 (en) | 2002-04-19 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US8905945B2 (en) | 2002-04-19 | 2014-12-09 | Dominique M. Freeman | Method and apparatus for penetrating tissue |
US8945910B2 (en) | 2003-09-29 | 2015-02-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9034639B2 (en) | 2002-12-30 | 2015-05-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US9089294B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9089678B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US9173992B2 (en) | 2006-03-13 | 2015-11-03 | Novo Nordisk A/S | Secure pairing of electronic devices using dual means of communication |
US9180050B2 (en) | 2004-08-17 | 2015-11-10 | California Institute Of Technology | Implantable intraocular pressure drain |
US9199035B2 (en) | 2008-05-08 | 2015-12-01 | Minipumps, Llc. | Drug-delivery pumps with dynamic, adaptive control |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9261476B2 (en) | 2004-05-20 | 2016-02-16 | Sanofi Sa | Printable hydrogel for biosensors |
US9271866B2 (en) | 2007-12-20 | 2016-03-01 | University Of Southern California | Apparatus and methods for delivering therapeutic agents |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9321581B2 (en) | 2012-10-12 | 2016-04-26 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9399094B2 (en) | 2006-06-06 | 2016-07-26 | Novo Nordisk A/S | Assembly comprising skin-mountable device and packaging therefore |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP1383560B1 (en) | 2001-04-06 | 2016-11-16 | F. Hoffmann-La Roche AG | Infusion set |
US9561000B2 (en) | 2003-12-31 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US9560993B2 (en) | 2001-11-21 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9782114B2 (en) | 2011-08-03 | 2017-10-10 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
US9795740B2 (en) | 2012-10-12 | 2017-10-24 | Eli Lilly And Company | Chemical engines and methods for their use, especially in the injection of highly viscous fluids |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9833183B2 (en) | 2008-05-30 | 2017-12-05 | Intuity Medical, Inc. | Body fluid sampling device—sampling site interface |
US9839386B2 (en) | 2002-04-19 | 2017-12-12 | Sanofi-Aventis Deustschland Gmbh | Body fluid sampling device with capacitive sensor |
US9897610B2 (en) | 2009-11-30 | 2018-02-20 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US9901687B2 (en) | 2008-01-03 | 2018-02-27 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US10330667B2 (en) | 2010-06-25 | 2019-06-25 | Intuity Medical, Inc. | Analyte monitoring methods and systems |
US10342926B2 (en) | 2016-05-26 | 2019-07-09 | Insulet Corporation | Single dose drug delivery device |
US10363372B2 (en) | 2016-08-12 | 2019-07-30 | Insulet Corporation | Plunger for drug delivery device |
US10383556B2 (en) | 2008-06-06 | 2019-08-20 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
US10433780B2 (en) | 2005-09-30 | 2019-10-08 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
US10441723B2 (en) | 2016-08-14 | 2019-10-15 | Insulet Corporation | Variable fill drug delivery device |
US10603440B2 (en) | 2017-01-19 | 2020-03-31 | Insulet Corporation | Cartridge hold-up volume reduction |
US10695485B2 (en) | 2017-03-07 | 2020-06-30 | Insulet Corporation | Very high volume user filled drug delivery device |
US10729386B2 (en) | 2013-06-21 | 2020-08-04 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
US10751478B2 (en) | 2016-10-07 | 2020-08-25 | Insulet Corporation | Multi-stage delivery system |
US10772550B2 (en) | 2002-02-08 | 2020-09-15 | Intuity Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US10780217B2 (en) | 2016-11-10 | 2020-09-22 | Insulet Corporation | Ratchet drive for on body delivery system |
US10874803B2 (en) | 2018-05-31 | 2020-12-29 | Insulet Corporation | Drug cartridge with drive system |
US10898656B2 (en) | 2017-09-26 | 2021-01-26 | Insulet Corporation | Needle mechanism module for drug delivery device |
US10973978B2 (en) | 2017-08-03 | 2021-04-13 | Insulet Corporation | Fluid flow regulation arrangements for drug delivery devices |
WO2021124331A1 (en) * | 2019-12-18 | 2021-06-24 | E3D A.C.A.L | Transfusion pump with an insertion device |
US11045603B2 (en) | 2017-02-22 | 2021-06-29 | Insulet Corporation | Needle insertion mechanisms for drug containers |
US11090434B2 (en) | 2015-11-24 | 2021-08-17 | Insulet Corporation | Automated drug delivery system |
US11147931B2 (en) | 2017-11-17 | 2021-10-19 | Insulet Corporation | Drug delivery device with air and backflow elimination |
US11229736B2 (en) | 2018-06-06 | 2022-01-25 | Insulet Corporation | Linear shuttle pump for drug delivery |
US11229741B2 (en) | 2012-03-30 | 2022-01-25 | Insulet Corporation | Fluid delivery device, transcutaneous access tool and fluid drive mechanism for use therewith |
US11280327B2 (en) | 2017-08-03 | 2022-03-22 | Insulet Corporation | Micro piston pump |
US11364341B2 (en) | 2015-11-25 | 2022-06-21 | Insulet Corporation | Wearable medication delivery device |
US11369735B2 (en) | 2019-11-05 | 2022-06-28 | Insulet Corporation | Component positioning of a linear shuttle pump |
US11446435B2 (en) | 2018-11-28 | 2022-09-20 | Insulet Corporation | Drug delivery shuttle pump system and valve assembly |
US11786668B2 (en) | 2017-09-25 | 2023-10-17 | Insulet Corporation | Drug delivery devices, systems, and methods with force transfer elements |
US11857763B2 (en) | 2016-01-14 | 2024-01-02 | Insulet Corporation | Adjusting insulin delivery rates |
US11865299B2 (en) | 2008-08-20 | 2024-01-09 | Insulet Corporation | Infusion pump systems and methods |
US11925790B2 (en) | 2017-02-17 | 2024-03-12 | Eli Lilly And Company | Processes and devices for delivery of fluid by chemical reaction |
US11929158B2 (en) | 2016-01-13 | 2024-03-12 | Insulet Corporation | User interface for diabetes management system |
USD1020794S1 (en) | 2018-04-02 | 2024-04-02 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
USD1024090S1 (en) | 2019-01-09 | 2024-04-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11969579B2 (en) | 2021-06-11 | 2024-04-30 | Insulet Corporation | Insulin delivery methods, systems and devices |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090054842A1 (en) * | 2003-11-18 | 2009-02-26 | Nanopass Technologies Ltd. | Enhanced penetration system and method for sliding microneedles |
EP2197518B1 (en) * | 2007-09-28 | 2019-10-30 | Calibra Medical LLC | Disposable infusion device with reuse lock-out |
WO2012042517A1 (en) * | 2010-09-27 | 2012-04-05 | Steadymed, Ltd. | Size-efficient drug-delivery device |
WO2012136528A1 (en) * | 2011-04-05 | 2012-10-11 | Pharmasens Ag | Dermally affixed device for intravenous access |
US8882711B2 (en) * | 2011-09-30 | 2014-11-11 | Animas Corporation | Insertion device for a medical conduit |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0258073A1 (en) * | 1986-06-16 | 1988-03-02 | Michel Pistor | Portable transcutanous injection device |
US4886499A (en) * | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
EP0494042A2 (en) * | 1990-12-31 | 1992-07-08 | S.I. SCIENTIFIC INNOVATIONS Ltd. | Liquid delivery device particularly useful for delivering drugs |
US5318540A (en) * | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
WO1995003078A1 (en) * | 1992-07-13 | 1995-02-02 | Elan Medical Technologies Limited | Liquid material dispenser and valve |
US5411480A (en) * | 1989-06-16 | 1995-05-02 | Science Incorporated | Fluid delivery apparatus |
WO1995013838A1 (en) | 1993-11-18 | 1995-05-26 | Elan Medical Technologies Limited | Intradermal drug delivery device |
WO1995032013A1 (en) * | 1994-05-23 | 1995-11-30 | Elan Medical Technologies Limited | Liquid delivery device |
WO1997010012A1 (en) | 1995-09-11 | 1997-03-20 | Elan Medical Technologies Limited | Medicament delivery device |
WO1997013544A1 (en) * | 1995-10-11 | 1997-04-17 | Science Incorporated | Fluid delivery device with bolus injection site |
WO1997041917A1 (en) * | 1996-05-07 | 1997-11-13 | Ceramatec, Inc. | Fluid delivery apparatus and method |
-
1998
- 1998-06-04 WO PCT/IE1998/000042 patent/WO1999062576A1/en not_active Application Discontinuation
- 1998-06-04 EP EP98925906A patent/EP1082151A1/en not_active Withdrawn
- 1998-06-04 CA CA002334174A patent/CA2334174A1/en not_active Abandoned
- 1998-06-04 JP JP2000551829A patent/JP2002516723A/en active Pending
- 1998-06-04 AU AU77859/98A patent/AU7785998A/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0258073A1 (en) * | 1986-06-16 | 1988-03-02 | Michel Pistor | Portable transcutanous injection device |
US4886499A (en) * | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US5411480A (en) * | 1989-06-16 | 1995-05-02 | Science Incorporated | Fluid delivery apparatus |
US5318540A (en) * | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
EP0494042A2 (en) * | 1990-12-31 | 1992-07-08 | S.I. SCIENTIFIC INNOVATIONS Ltd. | Liquid delivery device particularly useful for delivering drugs |
WO1995003078A1 (en) * | 1992-07-13 | 1995-02-02 | Elan Medical Technologies Limited | Liquid material dispenser and valve |
WO1995013838A1 (en) | 1993-11-18 | 1995-05-26 | Elan Medical Technologies Limited | Intradermal drug delivery device |
WO1995032013A1 (en) * | 1994-05-23 | 1995-11-30 | Elan Medical Technologies Limited | Liquid delivery device |
WO1997010012A1 (en) | 1995-09-11 | 1997-03-20 | Elan Medical Technologies Limited | Medicament delivery device |
WO1997013544A1 (en) * | 1995-10-11 | 1997-04-17 | Science Incorporated | Fluid delivery device with bolus injection site |
WO1997041917A1 (en) * | 1996-05-07 | 1997-11-13 | Ceramatec, Inc. | Fluid delivery apparatus and method |
Cited By (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6530900B1 (en) | 1997-05-06 | 2003-03-11 | Elan Pharma International Limited | Drug delivery device |
WO2001089607A3 (en) * | 2000-05-23 | 2002-02-28 | Elan Pharma Int Ltd | Gas driven drug delivery device |
JP2003534058A (en) * | 2000-05-23 | 2003-11-18 | エラン ファーマ インターナショナル,リミティド | Drug supply device |
JP2012152597A (en) * | 2000-05-23 | 2012-08-16 | Elan Pharma Internatl Ltd | Drug delivery device |
EP2308365A2 (en) | 2000-06-27 | 2011-04-13 | Intuity Medical, Inc. | Analyte monitor |
US7530964B2 (en) | 2000-06-30 | 2009-05-12 | Elan Pharma International Limited | Needle device and method thereof |
WO2002002165A3 (en) * | 2000-06-30 | 2002-05-30 | Elan Pharma Int Ltd | Needle device and method of operation thereof |
WO2002002165A2 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharma International Limited | Needle device and method of operation thereof |
US8158143B2 (en) | 2000-07-14 | 2012-04-17 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
EP1383560B1 (en) | 2001-04-06 | 2016-11-16 | F. Hoffmann-La Roche AG | Infusion set |
US9694144B2 (en) | 2001-06-12 | 2017-07-04 | Sanofi-Aventis Deutschland Gmbh | Sampling module device and method |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9937298B2 (en) | 2001-06-12 | 2018-04-10 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9802007B2 (en) | 2001-06-12 | 2017-10-31 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8845550B2 (en) | 2001-06-12 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP1438091A4 (en) * | 2001-10-04 | 2007-07-11 | Smiths Medical Md Inc | Right angle safety needle |
EP1438091A2 (en) * | 2001-10-04 | 2004-07-21 | Smiths Medical MD, Inc. | Right angle safety needle |
WO2003028784A2 (en) | 2001-10-04 | 2003-04-10 | Smiths Medical Md, Inc. | Right angle safety needle |
US7066922B2 (en) | 2001-10-26 | 2006-06-27 | Massachusetts Institute Of Technology | Transdermal transport device with suction |
US6981977B2 (en) | 2001-10-26 | 2006-01-03 | Atrium Medical Corporation | Body fluid cartridge exchange platform device |
US9560993B2 (en) | 2001-11-21 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US10772550B2 (en) | 2002-02-08 | 2020-09-15 | Intuity Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9072842B2 (en) | 2002-04-19 | 2015-07-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9724021B2 (en) | 2002-04-19 | 2017-08-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9498160B2 (en) | 2002-04-19 | 2016-11-22 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US9907502B2 (en) | 2002-04-19 | 2018-03-06 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9839386B2 (en) | 2002-04-19 | 2017-12-12 | Sanofi-Aventis Deustschland Gmbh | Body fluid sampling device with capacitive sensor |
US8690796B2 (en) | 2002-04-19 | 2014-04-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9339612B2 (en) | 2002-04-19 | 2016-05-17 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8845549B2 (en) | 2002-04-19 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US8905945B2 (en) | 2002-04-19 | 2014-12-09 | Dominique M. Freeman | Method and apparatus for penetrating tissue |
US9089678B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9089294B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9186468B2 (en) | 2002-04-19 | 2015-11-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9034639B2 (en) | 2002-12-30 | 2015-05-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US10034628B2 (en) | 2003-06-11 | 2018-07-31 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
EP1502613A1 (en) * | 2003-08-01 | 2005-02-02 | Novo Nordisk A/S | Needle device with retraction means |
US8945910B2 (en) | 2003-09-29 | 2015-02-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US9561000B2 (en) | 2003-12-31 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US9261476B2 (en) | 2004-05-20 | 2016-02-16 | Sanofi Sa | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9180050B2 (en) | 2004-08-17 | 2015-11-10 | California Institute Of Technology | Implantable intraocular pressure drain |
US8021357B2 (en) | 2005-05-27 | 2011-09-20 | Olympus Corporation | Body-insertable apparatus |
US10433780B2 (en) | 2005-09-30 | 2019-10-08 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
WO2007079115A3 (en) * | 2005-12-28 | 2007-11-29 | Smiths Medical Md Inc | Removable sharps device for accessing a portal reservoir |
US7510543B2 (en) | 2005-12-28 | 2009-03-31 | Smiths Medical Md, Inc. | Removable sharps device for accessing a portal reservoir |
AU2006332793B2 (en) * | 2005-12-28 | 2011-05-26 | Smiths Medical Asd, Inc. | Removable sharps device for accessing a portal reservoir |
US9173992B2 (en) | 2006-03-13 | 2015-11-03 | Novo Nordisk A/S | Secure pairing of electronic devices using dual means of communication |
US8308686B2 (en) | 2006-03-14 | 2012-11-13 | The University Of Southern California | MEMS device and method for delivery of therapeutic agents |
US9693894B2 (en) | 2006-03-14 | 2017-07-04 | The University Of Southern California | MEMS device and method for delivery of therapeutic agents |
US7887508B2 (en) | 2006-03-14 | 2011-02-15 | The University Of Southern California | MEMS device and method for delivery of therapeutic agents |
US9399094B2 (en) | 2006-06-06 | 2016-07-26 | Novo Nordisk A/S | Assembly comprising skin-mountable device and packaging therefore |
US9308124B2 (en) | 2007-12-20 | 2016-04-12 | University Of Southern California | Apparatus and methods for delivering therapeutic agents |
US9271866B2 (en) | 2007-12-20 | 2016-03-01 | University Of Southern California | Apparatus and methods for delivering therapeutic agents |
US10117774B2 (en) | 2007-12-20 | 2018-11-06 | University Of Southern California | Apparatus and methods for delivering therapeutic agents |
US9901687B2 (en) | 2008-01-03 | 2018-02-27 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
CN104353150A (en) * | 2008-05-08 | 2015-02-18 | 迷你泵有限责任公司 | Implantable pums and cannulas therefor |
US8348897B2 (en) | 2008-05-08 | 2013-01-08 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
CN102202719A (en) * | 2008-05-08 | 2011-09-28 | 迷你泵有限责任公司 | Implantable pums and cannulas therefor |
US9623174B2 (en) | 2008-05-08 | 2017-04-18 | Minipumps, Llc | Implantable pumps and cannulas therefor |
WO2009137780A2 (en) * | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable pumps and cannulas therefor |
US9283322B2 (en) | 2008-05-08 | 2016-03-15 | Minipumps, Llc | Drug-delivery pump with dynamic, adaptive control |
US9199035B2 (en) | 2008-05-08 | 2015-12-01 | Minipumps, Llc. | Drug-delivery pumps with dynamic, adaptive control |
US9162024B2 (en) | 2008-05-08 | 2015-10-20 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US8231609B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9107995B2 (en) | 2008-05-08 | 2015-08-18 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9987417B2 (en) | 2008-05-08 | 2018-06-05 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
US8231608B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9050407B2 (en) | 2008-05-08 | 2015-06-09 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
US8486278B2 (en) | 2008-05-08 | 2013-07-16 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9861525B2 (en) | 2008-05-08 | 2018-01-09 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US8529538B2 (en) | 2008-05-08 | 2013-09-10 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9849238B2 (en) | 2008-05-08 | 2017-12-26 | Minipumps, Llc | Drug-delivery pump with intelligent control |
WO2009137780A3 (en) * | 2008-05-08 | 2010-04-01 | Replenish Pumps, Llc | Implantable pums and cannulas therefor |
US9833183B2 (en) | 2008-05-30 | 2017-12-05 | Intuity Medical, Inc. | Body fluid sampling device—sampling site interface |
US11045125B2 (en) | 2008-05-30 | 2021-06-29 | Intuity Medical, Inc. | Body fluid sampling device-sampling site interface |
US10383556B2 (en) | 2008-06-06 | 2019-08-20 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
US11553860B2 (en) | 2008-06-06 | 2023-01-17 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
US11865299B2 (en) | 2008-08-20 | 2024-01-09 | Insulet Corporation | Infusion pump systems and methods |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US9897610B2 (en) | 2009-11-30 | 2018-02-20 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US11933789B2 (en) | 2009-11-30 | 2024-03-19 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US11002743B2 (en) | 2009-11-30 | 2021-05-11 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US10330667B2 (en) | 2010-06-25 | 2019-06-25 | Intuity Medical, Inc. | Analyte monitoring methods and systems |
US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9782114B2 (en) | 2011-08-03 | 2017-10-10 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
US11051734B2 (en) | 2011-08-03 | 2021-07-06 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
US11672452B2 (en) | 2011-08-03 | 2023-06-13 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
US11382544B2 (en) | 2011-08-03 | 2022-07-12 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
US11229741B2 (en) | 2012-03-30 | 2022-01-25 | Insulet Corporation | Fluid delivery device, transcutaneous access tool and fluid drive mechanism for use therewith |
US11684713B2 (en) | 2012-03-30 | 2023-06-27 | Insulet Corporation | Fluid delivery device, transcutaneous access tool and insertion mechanism for use therewith |
US9795740B2 (en) | 2012-10-12 | 2017-10-24 | Eli Lilly And Company | Chemical engines and methods for their use, especially in the injection of highly viscous fluids |
US9321581B2 (en) | 2012-10-12 | 2016-04-26 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
US9861750B2 (en) | 2012-10-12 | 2018-01-09 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
US10046116B2 (en) | 2012-10-12 | 2018-08-14 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
US10729386B2 (en) | 2013-06-21 | 2020-08-04 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
US11090434B2 (en) | 2015-11-24 | 2021-08-17 | Insulet Corporation | Automated drug delivery system |
US11744944B2 (en) | 2015-11-24 | 2023-09-05 | Insulet Corporation | Wearable automated medication delivery system |
US11364341B2 (en) | 2015-11-25 | 2022-06-21 | Insulet Corporation | Wearable medication delivery device |
US11929158B2 (en) | 2016-01-13 | 2024-03-12 | Insulet Corporation | User interface for diabetes management system |
US11857763B2 (en) | 2016-01-14 | 2024-01-02 | Insulet Corporation | Adjusting insulin delivery rates |
US10363374B2 (en) | 2016-05-26 | 2019-07-30 | Insulet Corporation | Multi-dose drug delivery device |
US10342926B2 (en) | 2016-05-26 | 2019-07-09 | Insulet Corporation | Single dose drug delivery device |
US10363372B2 (en) | 2016-08-12 | 2019-07-30 | Insulet Corporation | Plunger for drug delivery device |
US11497856B2 (en) | 2016-08-14 | 2022-11-15 | Insulet Corporation | Drug delivery device with indicator |
US10441723B2 (en) | 2016-08-14 | 2019-10-15 | Insulet Corporation | Variable fill drug delivery device |
US11439765B2 (en) | 2016-08-14 | 2022-09-13 | Insulet Corporation | Variable fill drug delivery device |
US10561797B2 (en) | 2016-08-14 | 2020-02-18 | Insulet Corporation | Drug delivery device with indicator |
US10751478B2 (en) | 2016-10-07 | 2020-08-25 | Insulet Corporation | Multi-stage delivery system |
US10780217B2 (en) | 2016-11-10 | 2020-09-22 | Insulet Corporation | Ratchet drive for on body delivery system |
US10603440B2 (en) | 2017-01-19 | 2020-03-31 | Insulet Corporation | Cartridge hold-up volume reduction |
US11633541B2 (en) | 2017-01-19 | 2023-04-25 | Insulet Corporation | Cartridge hold-up volume reduction |
US11925790B2 (en) | 2017-02-17 | 2024-03-12 | Eli Lilly And Company | Processes and devices for delivery of fluid by chemical reaction |
US11045603B2 (en) | 2017-02-22 | 2021-06-29 | Insulet Corporation | Needle insertion mechanisms for drug containers |
US10695485B2 (en) | 2017-03-07 | 2020-06-30 | Insulet Corporation | Very high volume user filled drug delivery device |
US10973978B2 (en) | 2017-08-03 | 2021-04-13 | Insulet Corporation | Fluid flow regulation arrangements for drug delivery devices |
US11280327B2 (en) | 2017-08-03 | 2022-03-22 | Insulet Corporation | Micro piston pump |
US11786668B2 (en) | 2017-09-25 | 2023-10-17 | Insulet Corporation | Drug delivery devices, systems, and methods with force transfer elements |
US10898656B2 (en) | 2017-09-26 | 2021-01-26 | Insulet Corporation | Needle mechanism module for drug delivery device |
US11147931B2 (en) | 2017-11-17 | 2021-10-19 | Insulet Corporation | Drug delivery device with air and backflow elimination |
USD1020794S1 (en) | 2018-04-02 | 2024-04-02 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
US10874803B2 (en) | 2018-05-31 | 2020-12-29 | Insulet Corporation | Drug cartridge with drive system |
US11229736B2 (en) | 2018-06-06 | 2022-01-25 | Insulet Corporation | Linear shuttle pump for drug delivery |
US11446435B2 (en) | 2018-11-28 | 2022-09-20 | Insulet Corporation | Drug delivery shuttle pump system and valve assembly |
USD1024090S1 (en) | 2019-01-09 | 2024-04-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11369735B2 (en) | 2019-11-05 | 2022-06-28 | Insulet Corporation | Component positioning of a linear shuttle pump |
WO2021124331A1 (en) * | 2019-12-18 | 2021-06-24 | E3D A.C.A.L | Transfusion pump with an insertion device |
US11969579B2 (en) | 2021-06-11 | 2024-04-30 | Insulet Corporation | Insulin delivery methods, systems and devices |
Also Published As
Publication number | Publication date |
---|---|
CA2334174A1 (en) | 1999-12-09 |
JP2002516723A (en) | 2002-06-11 |
AU7785998A (en) | 1999-12-20 |
EP1082151A1 (en) | 2001-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6186982B1 (en) | Subcutaneous drug delivery device with improved filling system | |
EP1082151A1 (en) | Gas driven drug delivery device | |
US6530900B1 (en) | Drug delivery device | |
AU2019200616B2 (en) | Integrated pierceable seal fluid pathway connection and drug containers for drug delivery pumps | |
AU2017203997B2 (en) | Insertion mechanisms having vented fluid pathways for drug delivery pumps | |
US5957891A (en) | Fluid delivery device with fill adapter | |
US6200293B1 (en) | Fluid delivery device with temperature controlled energy source | |
US6537249B2 (en) | Multiple canopy | |
US5693019A (en) | Fluid delivery apparatus | |
US5743879A (en) | Medicament dispenser | |
US5779676A (en) | Fluid delivery device with bolus injection site | |
US6007518A (en) | Fluid delivery device with conformable ullage and fill assembly | |
EP1039947A1 (en) | Medicament dispenser and cooperating reservoir fill assembly | |
KR20200044070A (en) | Optionally mechanically operable pre-charged infusion pump unit | |
JP2003265608A (en) | Collecting tool | |
TW418101B (en) | Subcutaneous drug delivery device with improved filling system | |
AU700421B2 (en) | Fluid delivery apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2334174 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998925906 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998925906 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998925906 Country of ref document: EP |